Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months

BACKGROUND AND OBJECTIVE: Sorafenib is recommended for treating advanced hepatocellular carcinoma. However, it is frequently discontinued because of adverse events, which greatly affects its therapeutic effects. Furthermore, because patients treated with sorafenib for a long period can presumably to...

Descripción completa

Detalles Bibliográficos
Autores principales: Katayama, Kazuhiro, Kiyota, Ryosuke, Imai, Toshihiro, Abe, Yutaro, Nawa, Tadatoshi, Wada, Hiroshi, Ohkawa, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243964/
https://www.ncbi.nlm.nih.gov/pubmed/30483103
http://dx.doi.org/10.1159/000493853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243964/
https://www.ncbi.nlm.nih.gov/pubmed/30483103
http://dx.doi.org/10.1159/000493853

Ejemplares similares